GlassScriptPhysician profile
Jonathan Ashton Olsen
NPI 1518287846
$59,775.57
in general payments reported to CMS, 2019-2025
31 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $109 · 2021: $299 · 2022: $11K · 2023: $41K · 2024: $6,793 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $5,777 · Consulting Fee: $5,033 · Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,450.00 |
| Travel and Lodging | $5,776.91 |
| Consulting Fee | $5,032.61 |
| Food and Beverage | $2,535.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54,883.32 | 2020-2024 | Nucala, Arexvy, Shingrix |
| Pharming Healthcare, INC. | $950.64 | 2019-2023 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $805.08 | 2019-2024 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $631.83 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $320.37 | 2019-2024 | Dupixent |
| Amgen INC. | $247.63 | 2021-2023 | Tezspire |
| Kaleo, INC. | $197.88 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $194.92 | 2019-2024 | |
| Boston Scientific Corporation | $158.01 | 2025 | General - Interventional Oncology |
| Adma Biomanufacturing LLC | $157.61 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.62 | 2020-2023 | Hyqvia |
| Biocryst US Sales Co., LLC | $130.72 | 2021-2023 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $125.46 | 2021-2023 | Airduo Digihaler |
| Genentech USA, INC. | $113.58 | 2021-2023 | Xolair |
| Csl Behring | $111.10 | 2023-2024 | Haegarda, Hizentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $100.54 | 2022-2023 | Xembify |
| Blueprint Medicines Corporation | $75.00 | 2024 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Sunovion Pharmaceuticals INC. | $64.00 | 2019 | |
| Pfizer INC. | $54.23 | 2019-2023 | |
| Abbvie INC. | $36.87 | 2020-2022 | |
| Bio Products Laboratory USA, INC. | $30.55 | 2022 | |
| Pulmonx Corporation | $25.35 | 2022 | |
| Novo Nordisk INC | $22.07 | 2021 | |
| Leo Pharma INC. | $21.21 | 2022 | |
| Optinose US, INC. | $18.81 | 2022 | |
| Strongbridge US INC. | $18.24 | 2019 | |
| Incyte Corporation | $17.82 | 2023 | Opzelura |
| Lilly USA, LLC | $14.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2019 | |
| Circassia INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.